Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: outcomes from the RELIEF study in patients across different severities and age groups


Source: Annual Congress 2002 - Asthma - Therapy and management -1
Session: Asthma - Therapy and management -1
Session type: Thematic Poster Session
Number: 395
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: outcomes from the RELIEF study in patients across different severities and age groups. Eur Respir J 2002; 20: Suppl. 38, 395

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 44s
Year: 2002

Safety of formoterol turbuhaler used as reliever in asthma: relationship with age and baseline treatment including regular long-acting β2-agonists (the RELIEF study)
Source: Eur Respir J 2002; 20: Suppl. 38, 44s
Year: 2002

Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study)
Source: Eur Respir J 2002; 20: Suppl. 38, 44s
Year: 2002

Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Safety of formoterol turbuhaler when used as a reliever therapy in asthma (the RELIEF study)
Source: Eur Respir J 2002; 20: Suppl. 38, 44s
Year: 2002

Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Formoterol Turbuhaler as reliever medication in patients with acute asthma
Source: Eur Respir J 2006; 27: 735-741
Year: 2006



Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use
Source: Eur Respir J 2004; 24: Suppl. 48, 289s
Year: 2004

Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017


QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015

Improved lung function and symptom control with formoterol on demand in asthma
Source: Eur Respir J 2006; 27: 504-510
Year: 2006



Efficacy of combined budesonide/formoterol delivered via turbuhaler on lung function and asthma control in asthmatic children
Source: Eur Respir J 2003; 22: Suppl. 45, 496s
Year: 2003

Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 52s
Year: 2002

Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013


Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 48s
Year: 2001

Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 509s
Year: 2004

Comparative study of 8-weeks treatment of asthma exacerbations in adults with high doses of budesonide versus fluticasone
Source: Eur Respir J 2001; 18: Suppl. 33, 97s
Year: 2001